Tirzepatide vs Semaglutide: Mounjaro vs Ozempic Compared for Vietnam 2026

The Quick Answer

Tirzepatide produces about 50% more weight loss than semaglutide in head-to-head clinical data. For a 90kg person, that gap translates to roughly 7 to 8 kg of additional weight loss over a year. The efficacy difference is real, consistent across multiple trials, and large enough to matter in practice.

Tirzepatide also tends to cause less nausea than semaglutide for most users, despite being more potent. The reason is the GIP co-agonism, which appears to buffer some of the GLP-1-induced GI effects. People who stopped semaglutide because of nausea often do better on tirzepatide.

Semaglutide has a 5-plus year longer track record. Ozempic has been in use since 2017 and has more real-world safety data than any other drug in this class. It is also significantly cheaper at both the pharmacy and research-grade level.

Both drugs are excellent. The decision comes down to your priorities. Start with semaglutide if cost matters or you want to start with the most-studied option. Start with tirzepatide if maximum results are the goal and you can absorb the higher cost. Neither choice is wrong.

What Each One Actually Is

Semaglutide is a single-agonist GLP-1 receptor drug developed by Novo Nordisk. It mimics the GLP-1 hormone your gut releases after eating, which tells your brain you are full and slows gastric emptying. It was FDA approved in 2017 as Ozempic for type 2 diabetes, and in 2021 as Wegovy specifically for obesity at a higher dose. It has the longest clinical history of any drug in this category and the largest real-world safety dataset.

Tirzepatide is a dual-agonist drug targeting both the GLP-1 receptor AND the GIP receptor, developed by Eli Lilly. GIP is a second gut hormone involved in fat storage, insulin response, and energy balance. Activating both receptors simultaneously produces stronger weight loss and, surprisingly, better GI tolerability than GLP-1 alone. It was FDA approved in 2022 as Mounjaro for diabetes and in 2023 as Zepbound specifically for obesity.

The GIP addition is the key difference. It is not just a "more powerful semaglutide." It works through a different and more complete mechanism, which is why the efficacy and tolerability numbers look the way they do. For the full technical breakdown of each, see the semaglutide profile and tirzepatide profile.

Efficacy Head to Head

The STEP trials are the pivotal semaglutide obesity data. At the 2.4mg weekly dose, participants lost an average of 14.9% of body weight over 68 weeks. Some participants reached 17.4% in the top-performing arms. These were large, well-run trials and the numbers hold up in real-world use.

The SURMOUNT trials are the tirzepatide obesity data. At the 15mg weekly dose, participants lost an average of 22.5% of body weight over 72 weeks. The top-performing participants in the highest dose groups reached 26.6%. These numbers were so far above what anyone expected that the field essentially had to revise its assumptions about how much weight loss was biologically achievable.

The SURMOUNT-5 trial put both drugs in a direct head-to-head comparison. Tirzepatide outperformed semaglutide by approximately 8 percentage points on weight loss at comparable study lengths. That gap is consistent with what the individual trial data showed.

For a concrete sense of scale: a 90kg person losing 14.9% loses about 13.4kg. The same person losing 22.5% loses about 20.25kg. The difference between those two outcomes is roughly 7kg. Over a year of treatment, that gap is significant. It is the primary reason many users upgrade from semaglutide to tirzepatide after plateauing.

Side by Side Comparison

The table makes tirzepatide look like the obvious choice on most rows. On raw efficacy, tolerability, and mechanism, it wins. But the last three rows tell a different story. Vietnam availability is more reliable for semaglutide. The pricing gap is real and matters over a multi-month protocol. And the cardiovascular benefit is proven for semaglutide but still under investigation for tirzepatide.

The practical read: if you are starting a 6-month weight loss protocol on a budget, semaglutide is the rational choice. If you are optimizing for maximum results and supply reliability is less important to you, tirzepatide is the better drug. Most experienced users who have access to both will choose tirzepatide. Most first-time users making a practical decision in Vietnam will start with semaglutide.

Side Effects and Tolerability

The most common side effects for both drugs are gastrointestinal: nausea, diarrhea, constipation, and occasionally vomiting. These are most intense in the first 4 to 8 weeks, typically during dose titration, and improve for most users after that.

Tirzepatide produces less nausea on average, which surprises most people given that it is the stronger drug. The GIP co-agonism appears to counteract some of the GLP-1-induced nausea, possibly through effects on gastric motility. After the first 2 weeks, many tirzepatide users report noticeably better GI comfort than they had on semaglutide. Vomiting is slightly more common on tirzepatide at the highest doses.

Diarrhea and constipation rates are similar between the two. Individual response varies significantly. Some people tolerate semaglutide perfectly and struggle with tirzepatide. Others find the reverse. There is no reliable way to predict which you will tolerate better before trying.

Both drugs carry the same serious risk warnings: medullary thyroid carcinoma (MTC), pancreatitis, gallbladder disease, and severe hypoglycemia in people on insulin. Neither is safer than the other on the rare-event side effects. These are class-level warnings, not brand-specific ones.

For people who stopped semaglutide specifically because of intolerable nausea, tirzepatide is worth trying. It does not always solve the problem but it does often enough to be the recommended next step. See the GLP-1 side effect management guide for protocols to reduce GI symptoms during the first weeks.

Vietnam Availability Reality

Ozempic (semaglutide) is registered with Vietnam's Drug Administration (DAV) and consistently available at major international hospitals. FV Hospital, Vinmec, Raffles Medical, and City International Hospital all carry it. Larger pharmacies in HCMC and Hanoi also stock it. A prescription from a Vietnamese doctor or international hospital is required for the pharmacy route. Wegovy is not registered as of early 2026 but appears occasionally at international hospitals.

Mounjaro (tirzepatide) is registered in Vietnam but supply is inconsistent. Call the hospital before your appointment. Some months it is readily available; other months it is not. Zepbound is not registered as of early 2026. When Mounjaro is available at pharmacy pricing, it costs significantly more than Ozempic at the equivalent weekly dose.

Research-grade versions of both molecules are available through the same supplier network at significantly lower cost than pharmacy pricing. The supplier verification process and COA requirements are identical for both. Most suppliers in the community-vetted network stock both.

For current pricing, hospital contacts, and the research-grade sourcing process, see the Semaglutide Vietnam 2026 guide and the Tirzepatide Vietnam 2026 guide for specifics on each.

Who Should Choose What

For Research-Grade Buyers

If you are already committed to the research-grade route, the decision framework from the previous sections still applies. The molecule is the same whether it comes from a pharmacy or a verified research supplier. The clinical data is relevant regardless of sourcing route.

The cost gap narrows at research-grade pricing. Tirzepatide is still more expensive per mg than semaglutide, but the difference is smaller than at pharmacy pricing. Most suppliers in the community supply index stock both. Availability is generally more reliable than the pharmacy route for either molecule.

COA verification matters more than brand choice. A clean semaglutide from a verified supplier with current third-party testing is better than a sketchy tirzepatide from an unverified source. Read the COA verification guide before committing to any supplier.

The most common approach in the community is starting with semaglutide for the first 2 to 3 months. This gives your body time to adapt to GLP-1 receptor agonism, lets you establish your baseline response, and gives you a reference point if you switch to tirzepatide later. Most people who go straight to tirzepatide do fine, but starting at semaglutide is the lower-risk path for first-time GLP-1 users.

For the Vietnam-specific legal and regulatory context, see the peptide legality guide and the GLP-1 Vietnam overview.

How to Switch Between Them

Switching from semaglutide to tirzepatide is the more common direction and the process is straightforward. Complete your last semaglutide dose on your normal schedule. Wait 7 days, which is approximately one semaglutide half-life. Start tirzepatide at 2.5mg and follow the standard titration schedule from there: 2.5mg for 4 weeks, then 5mg for 4 weeks, then escalating in 2.5mg increments every 4 weeks as tolerated up to 15mg.

Do not skip the 2.5mg starting dose even if you were on a high semaglutide dose. The GIP receptor is new territory for your body and the titration ramp exists for a reason. Users who jump straight to 5mg or higher after a semaglutide taper consistently report more GI side effects in the first month.

Switching from tirzepatide back to semaglutide (less common, usually for cost reasons) follows the same basic logic. Complete the last tirzepatide dose. Wait 7 days. Start semaglutide at 0.25mg and titrate normally. Expect appetite to return faster than it did when you first started tirzepatide, as the GIP receptor contribution disappears.

Running both simultaneously is not recommended. The side effect risk multiplies without meaningful additional efficacy benefit. If you want something stronger than either drug alone, retatrutide adds a third receptor target (glucagon) and produces higher weight loss than both. See the full comparison of retatrutide vs tirzepatide for that decision.

What About Retatrutide?

If you have been researching this space, you have probably encountered retatrutide. It is the triple-agonist drug in Phase 3 trials that adds glucagon receptor activation on top of GLP-1 and GIP. Phase 3 data shows 28.7% average weight loss, higher than both tirzepatide and semaglutide. The question is whether you should skip both of these and go straight to the next generation.

For most people reading this guide, the honest answer is no. Retatrutide is not FDA approved yet (expected 2026 to 2027 at the earliest). It has a significantly smaller safety dataset than either tirzepatide or semaglutide, less real-world usage, and is only available in the grey market as a research chemical. The efficacy advantage is real but so is the additional uncertainty.

Retatrutide makes sense for experienced users who have already completed a GLP-1 protocol and want the next tier of performance. For someone starting their first weight loss protocol, the safer and better-evidenced choice is still tirzepatide or semaglutide. See the retatrutide vs tirzepatide comparison for that decision.

The Bottom Line

Tirzepatide is the more effective drug on most metrics and is the current gold standard for GLP-1 weight loss. The clinical data is clear and consistent. If your primary goal is maximum weight loss and you can manage the higher cost and intermittent supply in Vietnam, tirzepatide is the better choice.

Semaglutide is cheaper, better-studied, and consistently available in Vietnam. It is the most-studied weight loss drug in history with proven cardiovascular benefits. The efficacy is lower, but 14.9% average weight loss is still a substantial result. For most new users in Vietnam, starting with semaglutide is the more practical decision, with the option to upgrade to tirzepatide later if needed.

Both drugs work. The tradeoffs are real on both sides. The decision is about what matters most to you right now, not about one drug being broken.

None of this is medical advice. Both of these are prescription medications. Talk to a doctor before starting either one.

Frequently Asked Questions